Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | +0.75% |
|
-11.62% | -28.29% |
Feb. 12 | C Worldwide Healthcare Select up 5.8% in January - divests Illumina | FW |
Jan. 22 | NovoCure Opens New Global Headquarters in Switzerland | MT |
Highlights: NovoCure Limited
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses: NovoCure Limited
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- With an enterprise value anticipated at 3.53 times the sales for the current fiscal year, the company turns out to be overvalued.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings Chart: NovoCure Limited
ESG chart: NovoCure Limited
Fundamentals | Valuation | Revisions of Fundamental Estimates | Capi.($) | ||
---|---|---|---|---|---|
10.25B | |||||
5.23B | |||||
- | 4.88B | ||||
- | 4.86B | ||||
- | 4.69B | ||||
4.46B | |||||
Average | 5.73B | ||||
Weighted average by Cap. |
Financials
Valuation
Revisions
Consensus
Business Predictability
ESG
Technical analysis
- Stock Market
- Equities
- NVCR Stock
- Ratings NovoCure Limited